What question did this study set out to answer?

This research aims to explore the associations between ulcerative colitis disease activity and the onset of depressive symptoms over a three-year period.

January 23, 2026

P0230Factors associated with the onset of depressive symptoms in ulcerative colitis patients in real-world Japanese patients: A YOURS registry study

Q: What does this research mean for the field?

Higher frequency of tenesmus and inadequate social support significantly increase the risk of depressive symptoms in ulcerative colitis patients. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

Key Result

Higher frequency of tenesmus (adjusted HR 2.178) and inadequate social support (adjusted HR 0.989) significantly increased the risk of depressive symptoms in ulcerative colitis patients.

Key Points

This research aims to explore the associations between ulcerative colitis disease activity and the onset of depressive symptoms over a three-year period.
Included patients aged ≥16 without depressive symptoms at baseline from a patient registry.
Conducted baseline assessments including demographics, disease activity scores, and psychosocial factors.
Collected annual follow-up data on depressive symptoms using patient-reported outcomes for up to three years.
Utilized Cox regression models to evaluate associations between baseline factors and the onset of depressive symptoms.
Of 2,006 patients, 280 developed depressive symptoms over three years.
Depression-free survival decreased significantly from 90.5% at one year to 78.2% at three years.
Baseline disease activity did not significantly correlate with the onset of depressive symptoms.
Higher frequency of tenesmus, inadequate social support, and greater perceived stress were significantly associated with increased depressive symptoms.

Structured PICO

What are the risk factors associated with the onset of depressive symptoms in patients with ulcerative colitis?

Population

1,551 patients aged ≥16 years with ulcerative colitis without depressive symptoms at baseline from the YOURS registry (median age 32 years, 52.9% male, 75.4% in remission at baseline).

Outcome

Onset of depressive symptoms (defined as HADS-D ≥8) over 3 yearspatient reported

Tenesmus, inadequate social support, and perceived stress, rather than baseline disease activity, are significant risk factors for the onset of depressive symptoms in patients with ulcerative colitis.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Background Patients with ulcerative colitis (UC) have more likely to experience depression and anxiety, especially during active disease. However, longitudinal data on the link between UC disease activity and depressive symptoms are limited. A prospective patient registry “YOURS” consisting of over 2,000 UC patients was established to explore how lifestyle and psychosocial factors affect clinical and mental health outcomes. This study aimed to examine the association between UC disease activity and the onset of depressive symptoms over 3 years. We explored modifiable risk factors for contributing to the onset of depressive symptoms. Methods Patients aged ≥16 years without depressive symptoms at baseline from YOURS registry were included. Baseline assessments covered demographics, disease activity (partial Mayo score), clinical characteristics, and lifestyle factors, and validated patient-reported outcomes, including the Hospital Anxiety and Depression Scale-Survey (HADS-D), Modified Medical Outcomes Study Social Support Survey (mMOS-SS), and Japanese version of the Perceived Stress Scale (JPSS). Annual follow-up data, including HADS-D, were collected for up to 3 years. moderate 0.001; often adjusted HR 2.178, p = 0.021), inadequate social support (adjusted HR 0.989, p 0.001), and greater perceived stress (adjusted HR 1.036, p = 0.003) were significantly associated with an increased risk of the onset of depressive symptoms Conclusion Tenesmus and inadequate social support were significant risk factors for the onset of depressive symptoms, while disease activity was not. Addressing tenesmus and enhancing social support may help prevent the onset of depressive symptoms in UC patients. Conflict of interest: Hisamatsu, Tadakazu: Grant support: Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Boston Scientific Corporation, Kissei Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd. Consulting: EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, JIMRO Co., Mochida Pharmaceutical Co. Ltd., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Abivax, MSD, Chugai. Lecture fee: EA Pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, JIMRO Co., Mochida Pharmaceutical Co., Ltd., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Kyorin Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Kissei Pharmaceutical Co. Ltd. Yamazaki, Hajime: Received lecture fees from Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Kowa, AstraZeneca, Kyorin Pharmaceutical, Mundipharma, and Takeda Pharmaceutical. Under contracts with Kyoto University, fees for consultation with Hajime Yamazaki were paid to Kyoto University by Takeda Pharmaceutical and Magmitt Pharmaceutical. Nagahori, Masakazu: I have received lecture fees and others from for the past three years from the companies below. Pfizer Inc. Takeda Pharmaceutical Company Limited Mochida Pharmaceutical Co., Ltd. AbbVie GK Mitsubishi Tanabe Pharma Corporation Zeria Pharmaceutical Co., Ltd. Janssen Pharmaceutical K.K. Kyorin Pharmaceutical Co., Ltd. Gilead Sciences, Inc. Kobayashi, Taku: Grant: AbbVie, Alfresa Pharma, EA Pharma, Gilead Sciences Inc, Nippon Kayaku Co. Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Sekisui Medical, Samsung Medicine Co. Ltd., Takeda Pharmaceutical Co. Ltd., Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Helmsley Charitable Trust, Celtrion, Kyorin Pharmaceutical, Miyarisan, Otsuka Holdings Personal Fees: Takeda Pharmaceutical Co. Ltd., Alfresa Pharma Corporation, Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Pfizer Japan Inc., Janssen Pharmaceutical K.K., JIMRO Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Kissei Pharmaceutical, MSD, Sekisui Medical Yonezawa, Maria: No conflict of interest Katsuura, Aya: Shareholder: Takeda Pharmaceutical Co. Ltd. Other: Employee of Takeda Pharmaceutical Co. Ltd. Hirose, Lisa: Employee of Takeda Pharmaceutical Co. Ltd. Fukuhara, Shunichi: No conflict of interest Matsuoka, Katsuyoshi: Grant: Abbvie Inc., Mochida Pharmaceutical Co., Ltd., EA Pharma, ZERIA Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., JIMRO Co., Ltd. Personal Fees: Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., Kyorin Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Gilead Sciences, Celltrion Healthcare, Bristol-Myers Squibb

AI에게 질문

Bookmark